I
Insilico Medicine
AI for Drug Discovery and Aging Research
Hong Kong (US offices in NYC, Boston)
400+
About Insilico Medicine
Industry:
AI Drug Discovery
Founded:
2014
Founders:
Alex Zhavoronkov
Status:
Private
Funding & Growth
Total Raised:
$400M+
Valuation:
$1B+
Stage:
Series D
Key Investors:
Warburg Pincus
Qiming Venture Partners
B Capital
✓ Pros
- • Pioneer in generative AI for drug discovery
- • Fast-moving clinical programs
- • Publications and visibility
- • Global team
- • Aging research focus
✗ Cons
- • Distributed team (timezone challenges)
- • Startup culture intensity
- • Hong Kong HQ complications
- • High expectations